Interview with Olivier Daubry, General Manager, Celgene France
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Address: 16/18, Rue du Quatre Septembre
75002 Paris
,France
Tel: +33 1 53 42 43 00
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
Celgene seeks to deliver truly innovative and life-changing drugs for our patients. It’s mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Thanks to the establishment of its structure in France, a 100% subsidiary of Celgene Corporation, Celgene France ensures its presence on the French health market. Celgene France, besides the marketing of drugs, will establish many clinical trials of new molecules derived from the R&D of Celgene. These, of course, will be conducted in cooperation with the most recognized French medical institutions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
Global Products
ISTODAX® (romidepsin) for injection
REVLIMID® (lenalidomide)
THALOMID® (thalidomide)
VIDAZA® (azacitidine for injection)
Services
LifebankUSA (placental and cord blood banking)
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
See our Cookie Privacy Policy Here
